An article published in the British Medical Journal 18 August 2009  compared the risk of acute myocardial infarction, heart failure, and death in patients with type 2 diabetes treated with rosiglitazone (also know as Avandia) and pioglitazone. The article concluded that among older patients with diabetes, pioglitazone is associated with a significantly lower risk of heart failure and death than is rosiglitazone.  The article concludes that there is a growing body of evidence that indicates the use of rosiglitazone is harmful and questions whether its use in any circumstances can be justified.

If you are concerned that you or a member of your family may have been affected by taking rosiglitazone, we suggest that you consult your medical advisers as soon as possible. Leigh Day & Co’s product liability team has unrivalled experience in dealing with claims relating to defective drugs and medical devices. If you would like to talk to one of our solicitors about a possible claim, please contact Gene Matthews or Jill Paterson on 0207 650 1311.